|
Mutation Information
|
Mutation Site
|
K219Q |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
NRTIs |
|
Country
|
Kenya;uganda |
Literature Information
|
PubMed PMID
|
33561143
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2021 |
|
Journal
|
PLoS medicine |
|
Title
|
HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. |
|
Author
|
Koss CA,Havlir DV,Ayieko J,Kwarisiima D,Kabami J,Chamie G,Atukunda M,Mwinike Y,Mwangwa F,Owaraganise A,Peng J,Olilo W,Snyman K,Awuonda B,Clark TD,Black D,Nugent J,Brown LB,Marquez C,Okochi H,Zhang K,Camlin CS,Jain V,Gandhi M,Cohen CR,Bukusi EA,Charlebois ED,Petersen ML,Kamya MR,Balzer LB |
|
Evidence
|
The other participant with drug resistance had 2-class ARV resistance, including transmitted NNRTI mutations (K103N, P225H), likely transmitted nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) mutations (D67N, K70R, K219Q; thymidine analogue mutations, conferring low-level TDF resistance), and an M184V mutation (conferring high-level FTC and 3TC resistance) that was either transmitted or acquired on PrEP.
|
|
|
HIV Mutation Detail Information